On this page
Risankizumab (brand name Skyrizi) is one of the newer biologic medicines for Crohn's disease (CD) and ulcerative colitis (UC). It was first used for psoriasis and is now recommended by NICE for moderate to severe IBD.
What is it and how does it work?
Risankizumab is an antibody, made in the laboratory, that blocks a chemical messenger called interleukin-23 (IL-23), which helps to drive inflammation in the gut. It is related to ustekinumab, which blocks IL-23 and also IL-12, but is more targeted. Mirikizumab and guselkumab work in the same way.
What is it used for?
Moderate to severe CD or UC that hasn't responded to, or can't be treated with, other medicines, which may include steroids, immunosuppressants and other biologics. Your IBD team will discuss whether it is the right choice for you.
Before you start
You will have blood tests, including checks for tuberculosis (TB), hepatitis B and C and HIV, and liver tests. Your vaccinations will be reviewed.
How is it given?
- Starting doses: three drips (infusions) into a vein, four weeks apart, in hospital or an infusion clinic.
- Then: an injection under the skin every 8 weeks. For Crohn's disease this is usually given with an on-body injector: a small device that sticks to your skin and slowly delivers the dose over about five minutes. For UC it is a pre-filled pen or syringe.
You can use the injections at home after training from your IBD nurse; they are delivered by a homecare company and kept in the fridge.
Many people notice an improvement during the first few weeks, though the full effect can take longer.
Liver tests
Risankizumab can occasionally affect the liver. You will have liver blood tests before you start, regularly during the first few months, and from time to time afterwards. Contact your team straight away if you notice yellowing of the skin or eyes, dark urine, pain in the upper right of the tummy, or unusual tiredness.
Side effects
Most people have few or no side effects. The more common ones are:
- Colds, sore throat and other mild infections of the nose and throat
- Headache and tiredness
- Redness, itching or bruising where you inject
- Joint pain
Infections. Risankizumab can make it harder to fight some infections. Contact your team or GP if you have a fever or feel unwell, and tell them you take risankizumab.
Rarely: allergic reactions and changes in liver tests (see above).
Because it is a newer medicine in IBD, there is less long-term experience than with older treatments. Your team will keep its safety under review.
Vaccinations
Don't have live vaccines while taking risankizumab, unless your specialist advises otherwise. Non-live vaccines are safe and recommended, including the yearly flu injection, COVID-19, pneumococcal and the non-live shingles vaccine. Ideally, have any vaccines you need before you start.
Pregnancy and breastfeeding
There is little experience of risankizumab in pregnancy. The patient leaflet advises women who could become pregnant to use effective contraception during treatment and for at least 21 weeks after the last dose, and, as a precaution, to avoid it during pregnancy. If you are planning a pregnancy, or become pregnant, talk to your IBD team straight away; don't stop the medicine on your own. Your team will weigh up the risks of the medicine against the risks of a flare-up. It is not known whether it passes into breast milk, so discuss breastfeeding with your team.
See Pregnancy and Inflammatory Bowel Disease.
Surgery, dental work and travel
Tell your surgeon or dentist that you take risankizumab before any procedure. With injections every 8 weeks, most trips can be planned around a dose. See Travel Insurance with Crohn's or Colitis.
If risankizumab does not work
Your team may switch you to another medicine, such as an anti-TNF (infliximab or adalimumab), vedolizumab or a tablet such as upadacitinib. See Medicines for Crohn's Disease and Ulcerative Colitis.
Never stop risankizumab without discussing it with your IBD team first.